stockportfolio.pro
Solid Biosciences Inc. (SLDB)
Healthcare · Biotechnology · NasdaqGS
Solid Biosciences Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $13.62M | $8.09M | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-21.54M | $-52.12M | $-74.80M | $-117.22M | $-88.29M | $-72.19M | $-85.98M | $-96.02M | $-124.70M | $-174.32M |
| Net margin | — | — | — | — | — | -530.0% | -1062.3% | — | — | — |
Source: Solid Biosciences Inc. SEC filings (10-K).
Explore 10 years of Solid Biosciences Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track SLDB in your portfolio →
Solid Biosciences Inc. financial history by metric
About Solid Biosciences Inc.
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Solid Biosciences Inc. — frequently asked questions
What is Solid Biosciences Inc.'s revenue?
Solid Biosciences Inc. (SLDB) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Solid Biosciences Inc. profitable?
No — SLDB reported a net loss of $-174.32M in fiscal 2025.
What is SLDB's P/E ratio?
Solid Biosciences Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Solid Biosciences Inc. have?
As of fiscal year 2025, SLDB carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Solid Biosciences Inc.'s market cap?
Solid Biosciences Inc. (SLDB) has a market capitalization of about $690.62M, based on the latest data in our nightly-refreshed cache.
When does Solid Biosciences Inc.'s fiscal year end?
SLDB's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Solid Biosciences Inc.'s official SEC filings (10-K and 10-Q), covering 10 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.